Eisai appoints new president for commercial operations unit

In her new role, Ms Schwalm will have full operating responsibility for leading Eisai Inc., the US commercial operation of Eisai Co., Ltd. She will report to Lonnel Coats, president & COO of Eisai Corporation of North America. Previously, Mr Coats held dual responsibilities, also serving as president & COO of Eisai Inc.

Ms Schwalm joins Eisai from Amgen, where over the course of her five-year tenure she rose to vice president and general manager of the US Oncology Business Unit, a group with annual revenues exceeding $5 billion.

Mr Coats said: “Ms Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families.”